CCM
VIR icon

Cinctive Capital Management’s Vir Biotechnology VIR Stock Holding History

Cinctive Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,755
Closed -$167K – 519
2025
Q4 		$167K Buy
27,755
+3,572
+15% +$21.3K 0.01% 376
2025
Q3 		$138K Sell
24,183
-63,988
-73% -$327K 0.01% 388
2025
Q2 		$444K Buy
88,171
+3,773
+4% +$20.2K 0.02% 319
2025
Q1 		$547K Buy
+84,398
New +$750K 0.04% 252

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Cinctive Capital Management's VIR Position: Q1 2026 in Review

Cinctive Capital Management sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 27,755 shares — an estimated $167K sold.

Cinctive Capital Management first reported a position in VIR in Q1 2025 and held it in 4 quarters. The position peaked at $547K in Q1 2025. 252 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Cinctive Capital Management reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 27,755 Vir Biotechnology shares in Q1 2026, an estimated $167K.
  • Cinctive Capital Management first reported a position in Vir Biotechnology in Q1 2025 and held it in 4 quarters.
  • Cinctive Capital Management's Vir Biotechnology position peaked at $547K in Q1 2025.
  • 252 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.